Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma.
British Journal of Dermatology, 07/18/2012
Anforth RM et al. – Administration of the mutant mutant BRAF (BRAFi) dabrafenib is associated with induction of keratinocytic proliferation, which in some cases develops features of low–grade malignancy. Highly oncogenic Human papilloma virus (HPV) infection is unlikely to be a contributor to the formation of squamous cell carcinomas (SCC) or verrucal keratoses.